Celadon Pharmaceuticals (UK) Today
| CEL Stock | 10.00 4.00 28.57% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Celadon Pharmaceuticals is trading at 10.00 as of the 25th of March 2025, a 28.57 percent decrease since the beginning of the trading day. The stock's lowest day price was 5.0. Celadon Pharmaceuticals has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 25th of December 2024 and ending today, the 25th of March 2025. Click here to learn more.
Moving against Celadon Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Celadon Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Celadon Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Celadon Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO CoFounder | James Short |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Drug Manufacturers-Specialty & Generic, Healthcare (View all Sectors) |
Celadon Pharmaceuticals PLC (CEL) is traded on London Exchange in UK and employs 27 people. Celadon Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 9.64 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Celadon Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Celadon Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Celadon Pharmaceuticals operates under Biotechnology sector and is part of Health Care industry. The entity has 68.85 M outstanding shares.
Celadon Pharmaceuticals generates negative cash flow from operations
Check Celadon Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationCeladon Pharmaceuticals holds a total of 68.85 Million outstanding shares. Celadon Pharmaceuticals PLC shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 64.8 percent of Celadon Pharmaceuticals outstanding shares that are owned by insiders signifies that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Celadon Ownership Details
Celadon Pharmaceuticals Risk Profiles
Although Celadon Pharmaceuticals' alpha and beta are two of the key measurements used to evaluate Celadon Pharmaceuticals' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 6.2 | |||
| Standard Deviation | 15.18 | |||
| Variance | 230.42 | |||
| Risk Adjusted Performance | 0.0079 |
Celadon Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Celadon Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Pattern Recognition Now
Pattern RecognitionUse different Pattern Recognition models to time the market across multiple global exchanges |
| All Next | Launch Module |
Celadon Pharmaceuticals Corporate Executives
Elected by the shareholders, the Celadon Pharmaceuticals' board of directors comprises two types of representatives: Celadon Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Celadon. The board's role is to monitor Celadon Pharmaceuticals' management team and ensure that shareholders' interests are well served. Celadon Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Celadon Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Paul Allen | CoFounder | Profile |
Other Information on Investing in Celadon Stock
Celadon Pharmaceuticals financial ratios help investors to determine whether Celadon Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Celadon with respect to the benefits of owning Celadon Pharmaceuticals security.